2026-03-31 Astellas Pharma Inc. “Announcement regarding top management personnel changes.”
2026-03-31 Astellas Pharma Inc. “Announcement regarding top management personnel changes.”
JP3942400007
2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indication for the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in combination with pembrolizumab for muscle-invasive bladder cancer already treated with cisplatin.”
2026-03-23 Astellas Pharma Inc. “The EMA has received an application for approval of an additional indic … 続きを読む
2026-03-09 Astellas Pharma Inc. “XOSPATA™ (gilteritinib) Topline results from the Phase III PASHA trial in treatment-naïve patients with FLT3 mutation-positive AML who are candidates for intensive chemotherapy.”
2026-03-09 Astellas Pharma Inc. “XOSPATA™ (gilteritinib) Topline results from the Phase III PASHA trial … 続きを読む
2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”
2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む